Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease
{{output}}
Introduction: This analysis of the phase 3 TRAILBLAZER-ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p-tau217) level can reliably monitor treatment-related amyloid clearance (TRAC) after donanem... ...
